Article in CHEST: Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy? Insight From the AMBITION Trial

Fauvel, C., Liu, Y., Correa-Jaque, P., Kanwar, M., Vizza, C. D., Lin, S., & Benza, R. L.  Background Based on results of the Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension (AMBITION) trial, upfront combination therapy is recommended for treatment-naive patients with low-risk pulmonary arterial hypertension (PAH). However, conflicting data exist whether adopting this treatment […]